Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma

被引：0
|
作者：
Izutsu, Koji [1 ]
Goto, Hideki [2 ]
Kizaki, Masahiro [3 ]
Yamaguchi, Masaki [4 ]
Fukuhara, Noriko [5 ]
Kato, Koji [6 ]
Saito, Toko [7 ]
Terui, Yasuhito [8 ]
Okubo, Sumiko [9 ]
Soshin, Tomomi [9 ]
Mukherjee, Nabanita [10 ]
Honda, Hideyuki [9 ]
Badawi, Mohamed [10 ]
Ross, Jeremy [10 ]
Ishizawa, Kenichi [11 ]
机构：
[1] Natl Canc Ctr, Tokyo, Japan
[2] Hokkaido Univ Hosp, Hokkaido, Japan
[3] Saitama Med Ctr, Saitama, Japan
[4] Ishikawa Prefecture Cent Hosp, Kanazawa, Ishikawa, Japan
[5] Tohoku Univ Hosp, Sendai, Miyagi, Japan
[6] Kyushu Univ Hosp, Fukuoka, Japan
[7] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[8] Saitama Med Univ Hosp, Saitama, Japan
[9] Abbvie GK, Tokyo, Japan
[10] AbbVie Inc, N Chicago, IL USA
[11] Yamagata Univ Hosp, Yamagata, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.280
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO50-5
引用
收藏
页码：S1428 / S1428
页数：1
相关论文
共 50 条
  • [31] Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: Precog 0404
    Cohen, Jonathon B.
    Jegede, Opeyemi
    Portell, Craig A.
    Hamadani, Mehdi
    Diefenbach, Catherine S.
    David, Kevin A.
    Fletcher, Christopher D.
    Landsburg, Daniel J.
    Mantha, Suparna
    Kahl, Brad S.
    BLOOD, 2022, 140 : 6487 - 6488
  • [32] A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404
    Cohen, Jonathon B.
    Portell, Craig A.
    Hamadani, Mehdi
    Jegede, Opeyemi
    Diefenbach, Catherine
    David, Kevin A.
    Fletcher, Christopher D.
    Landsburg, Daniel J.
    Kahl, Brad S.
    BLOOD, 2019, 134
  • [33] Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
    Hillmen, Peter
    Rawstron, Andy C.
    Brock, Kristian
    Munoz-Vicente, Samuel
    Yates, Francesca J.
    Bishop, Rebecca
    Boucher, Rebecca
    MacDonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John G.
    Patten, Piers E. M.
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher P.
    Forconi, Francesco
    Munir, Talha
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) : 2722 - +
  • [34] Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry
    Baggio, Diva
    Wellard, Cameron
    Chung, Eliza
    Talaulikar, Dipti
    Keane, Colm
    Opat, Stephen
    Giri, Pratyush
    Minson, Adrian
    Cheah, Chan Yoon
    Armytage, Tasman
    Lee, Denise
    Chong, Geoffrey
    Johnston, Anna
    Cochrane, Tara
    Waters, Neil
    Hamad, Nada
    Wood, Erica M.
    Hawkes, Eliza A.
    LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 621 - 627
  • [35] The combination of ibrutinib and venetoclax (ABT-199) to achieve complete remissions in patients with relapsed/refractory mantle cell lymphoma: Preliminary results of the phase II AIM study.
    Tam, Constantine Si Lun
    Roberts, Andrew Warwick
    Anderson, Mary Ann
    Dawson, Sarah-Jane
    Hicks, Rodney J.
    Pott, Christiane
    Westerman, David A.
    Burke, Glenda
    Kamel, Sarah
    Dreyling, Martin H.
    Dawson, Mark A.
    Seymour, John Francis
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] THE COMBINATION OF IBRUTINIB AND VENETOCLAX (ABT-199) RAPIDLY ACHIEVES COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PRELIMINARY RESULTS OF THE PHASE II AIM STUDY
    Tam, C.
    Roberts, A.
    Anderson, M. A.
    Dawson, S. J.
    Hicks, R.
    Pott, C.
    Westerman, D.
    Burke, G.
    Kamel, S.
    Dreyling, M.
    Dawson, M.
    Seymour, J.
    HAEMATOLOGICA, 2016, 101 : 103 - 103
  • [37] Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis
    Melani, Christopher
    Lakhotia, Rahul
    Pittaluga, Stefania
    Miljkovic, Milos D.
    Phelan, James D.
    Muppidi, Jagan R.
    Thomas, Craig J.
    Ceribelli, Michele
    Juanitez, Anna Marie
    Pradhan, Amynah
    Hillsman, Amy
    Steinberg, Seth M.
    Jaffe, Elaine S.
    Roschewski, Mark
    Staudt, Louis M.
    Wilson, Wyndham H.
    BLOOD, 2021, 138
  • [38] Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma
    Zhou, Zhiyuan
    Zhang, Lei
    Wang, Xinhua
    Li, Xin
    Li, Ling
    Fu, Xiaorui
    Zhang, Xudong
    Li, Zhaoming
    Sun, Zhenchang
    Zhang, Mingzhi
    ANNALS OF HEMATOLOGY, 2021, 100 (06) : 1509 - 1516
  • [39] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
    Fisher, Richard I.
    Bernstein, Steven H.
    Kahl, Brad S.
    Djulbegovic, Benjamin
    Robertson, Michael J.
    de Vos, Sven
    Epner, Elliot
    Krishnan, Amrita
    Leonard, John P.
    Lonial, Sagar
    Stadtmauer, Edward A.
    O'Connor, Owen A.
    Shi, Hongliang
    Boral, Anthony L.
    Goy, Andre
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) : 4867 - 4874
  • [40] Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study
    Zhang, Yuchen
    Liu, Panpan
    Cai, Jun
    Jing, Hongmei
    Zou, Liqun
    Huang, Huiqiang
    Wu, Yuanbin
    Li, Wenyu
    Zhong, Liye
    Jin, Xueli
    Ye, Xu
    Feng, Ru
    Zhang, Huilai
    Zhang, Liling
    Lin, Lie
    Sun, Xiuhua
    Tian, Yuyang
    Xia, Zhongjun
    Li, Zhiming
    Huang, He
    Xia, Yi
    Cai, Qingqing
    CANCER MEDICINE, 2022, 11 (22): : 4134 - 4145
12345